Lack of anticonvulsant tolerance and benzodiazepine receptor down regulation with imidazenil in rats
Abstract
- 1
Development of anticonvulsant tolerance and benzodiazepine (BZD) receptor down-regulation has been reported to occur upon chronic administration of conventional BZDs. We compared the effect of chronic treatment with imidazenil, a new BZD partial agonist, and diazepam in rats.
- 2
After acute administration, imidazenil was more potent though less effective than diazepam in protecting from bicuculline-induced seizure. The time-course analysis of two peak equieffective doses of imidazenil (2.5 μmol kg−1 p.o.) and diazepam (35 μmol kg−1, p.o.) showed a longer lasting action of the former drug.
- 3
The anticonvulsant efficacy of diazepam (35 μmol kg−1, p.o.) was reduced in rats given chronic diazepam (35 μmol kg−1, p.o., 3 times a day for 8–15 days). No tolerance to imidazenil (2.5 μmol kg−1, p.o.) was apparent after 130-day administration with imidazenil (2.5 μmol kg−1, p.o., 3 times a day).
- 4
Plasma levels of imidazenil and diazepam, assessed 30 min after administration, were not changed in chronically treated animals.
- 5
In rats made tolerant to diazepam, the maximum number of [3H]-flumazenil binding sites were reduced in both cerebral cortex (−36%) and cerebellum (−42%). No changes in [3H]-flumazenil binding were found in chronic imidazenil-treated rats.
- 6
Specific [3H]-flumazenil binding in vivo was decreased in the forebrain of chronic diazepam- but not of chronic imidazenil-treated animals.
- 7
These data indicate that imidazenil possesses a very low tolerance potential to its anticonvulsant activity and does not affect BZD receptor density even after prolonged administration.